MedCity News
This week, read new developments at Carrum Health, Seven Bridges, CARISMA Therapeutics, and more.
Shares0
Seven Bridges recently announced the formation of its strategic advisory board tasked with advising Seven Bridges leadership team in its mission to accelerate scientific discovery and speed the path from raw experimental data to new treatments and diagnostics. The appointment of three leaders with significant experience in healthcare and artificial intelligence will aid the company exploring new health-focused opportunities and bolster the company’s work with biopharmaceutical and academic researchers to significantly decrease the time, cost, and risk in the discovery-through-
commercialization cycle for novel precision medicines and therapies.
4Bio Capital
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
4BIO Capital Joins Investor Syndicate in CARISMA Therapeutics’ Second Closing of $59 Million Series B Round
Press Release
1 March 2021
LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announced it has become an investor in CARISMA Therapeutics, a biopharmaceutical company focused on discovering and developing innovative immunotherapies.
4BIO participated in the second closing of CARISMA’s $59 million Series B round, alongside founding investors IP Group, Inc. and Penn Medicine, joining the initial Series B investor syndicate of SymBiosis II, Solasta Ventures, Livzon Pharmaceuticals Group, AbbVie Ventures, HealthCap, Wellington Partners, TPG Biotech, Agent Capital and MRL Venture Fund.
/PRNewswire/ CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the.
CARISMA Therapeutics Completes Series B Financing Totaling $59 Million prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.